Progressing bacterial-derived extracellular vesicles to clinical stage
Bacterially derived extracellular vesicles (EVs) such as Outer Membrane Vesicles (OMVs) have emerged as an attractive new modality for both immunotherapy and as vectors for nucleotides and proteins. Being a ...
Manufacturing stem cells for regenerative therapies
Stem cells have revolutionized the field of regenerative medicine, offering promising solutions for various medical conditions, including difficult-to-heal skin wounds. This review focuses on the background and manufacturing processes of ...
Driving therapeutic innovation with OMVs and EVs
Outer membrane vesicles (OMVs) and extracellular vesicles (EVs) are unlocking new possibilities in vaccines and therapeutics. OMVs, with their natural adjuvant properties and capacity to carry antigens, enhance immune responses, ...
Robotic gloveless isolator technology enhances regional production of advanced therapeutics
To meet growing demands of advanced therapy manufacturing, production architectures must shift towards agile, efficient manufacturing systems. By integrating robotic gloveless isolator (RGI) technology into bioproduction, manufacturers can meet the ...
FAQ: Extracellular vesicles, outer membrane vesicles and exosomes
This FAQ aims to provide a comprehensive understanding of EVs. Whether you’re new to the concept or looking to deepen your knowledge, this guide will offer valuable insights into the ...
From lab to clinic: Large-scale recombinant protein production explained
Recombinant protein manufacturing has transformed biotechnology, enabling the production of therapeutic proteins, industrial enzymes, and bioengineered materials. The growing demand for recombinant proteins across regenerative medicine, disease diagnostics, and biopharmaceuticals ...
Personalized medicine and the CDMO: Adapting to a new era of healthcare
Neoantigen cancer vaccines represent a groundbreaking advancement in personalized medicine, offering tailored cancer treatments designed for each patient’s unique tumor profile. These therapies require rapid turnaround from tumor identification to ...
The expanding biologics CDMO market: Innovative modalities and the role of NorthX Biologics
The pharmaceutical industry is experiencing a rapid transformation as advanced biologics – viral vectors, recombinant proteins, plasmid DNA, and cell and gene therapies – take center stage. With over 14,800 ...
Protein science and the future of biotherapeutics
The study of proteins is transforming our understanding of human biology and disease, enabling breakthroughs in diagnostics, drug development, and advanced therapies. In this article, Mathias Uhlén, Professor of Microbiology ...